Premium
Plasma 11‐dehydrothromboxane B 2 : a reliable indicator of platelet hyperfunction in patients with ischemic stroke
Author(s) -
Satoh K.,
Imaizumi T.,
Yoshida H.,
Hiramoto M.,
Konta A.,
Takamatsu S.
Publication year - 1991
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1991.tb04657.x
Subject(s) - platelet , stroke (engine) , radioimmunoassay , medicine , ischemic stroke , thrombosis , hyperfunction , plasma levels , blood plasma , in vivo , gastroenterology , endocrinology , surgery , ischemia , biology , microbiology and biotechnology , mechanical engineering , engineering
The plasma level of 11‐dehydrothromboxane B 2 (11‐dehydroTXB 2 ) is free from artifactual increase during blood sampling, and it can be a reliable indicator of TXA 2 production in vivo. We have estimated plasma 11‐dehydroTXB 2 in patients with ischemic stroke. Subjects studied were 29 patients with cerebral thrombosis (62 ± 9 years old) and 41 healthy controls (61 ± 1 years old). Plasma 11‐dehydroTXB 2 and TXB 2 were determined by radioimmunoassay. Plasma 11‐dehydroTXB 2 levels in patients and controls were 5.4 ± 2.5 and 1.8 ± 0.9 pg/ml, respectively, and the difference was significant (p < 0.001). Plasma TXB 2 also was higher in patients than in controls: 401 ± 61 vs 311 ± 51 pg/ml (p < 0.05). However, the 11‐dehydroTXB 2 was found to be a more effective parameter to distinguish between stroke patients and controls. Estimation of plasma 11‐dehydroTXB 2 levels is a reliable method to detect platelet hyperfunction in stroke patients.